ArticleCureus2025
Frequency of Zinc Deficiency Among Thalassemia Major Patients: A Comparative Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBeta thalassemia major is a common autosomal recessive blood disorder that arises due to reduced or absent synthesis of the globin chain of hemoglobin. It serves as an alternative therapy in transfusion-dependent beta thalassemia to reduce the burden of blood transfusions. The primary objective of this study was to ascertain the frequency of zinc deficiency among two distinct populations of thalassemic children: those with transfusion-dependent thalassemia and those on fetal hemoglobin (HbF) augmentation therapy (hydroxyurea). The secondary objective of this study was to evaluate the effect of hydroxyurea on zinc levels in patients receiving this drug therapy.
methodsA comparative cross-sectional study was conducted over a period of two months following approval from the Institutional Review Board. Thalassemic patients were divided into two groups for analysis: regularly transfused patients and those on HbF augmentation therapy (hydroxyurea) with infrequent or no blood transfusions.
resultsA total of 100 patients were enrolled in this study, with a mean age of 7.7 ± 3.2 years, of which 51% were male and 49% were female. The frequency of zinc deficiency among individuals receiving regular transfusions was 56%, while the frequency of zinc deficiency among individuals taking hydroxyurea with infrequent transfusions was 42%. Although the frequency of zinc deficiency was higher among patients receiving blood transfusions, it was not statistically significant (p = 0.161).
conclusionIn this study, it was found that hydroxyurea-treated thalassemic children had a lower frequency of zinc deficiency compared to transfusion-dependent thalassemic children; however, this difference was not statistically significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.